Skip to content
Screener

Monopar Therapeutics MNPR Asset turnover

Asset turnover at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.7×0.0×
Bausch Health Companies logo
Bausch Health CompaniesBHC
0.4×0.0×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.6×+0.1×
Wave Life Sciences logo
Wave Life SciencesWVE
0.5×+0.3×
Prime Medicine logo
Prime MedicinePRME
0×0.0×

Other financials

Income statement

See full
Revenue-—
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19—

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$798.6M+307%
Enterprise value$746.28M+378%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0×0.0×
Current ratio56×—

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

total revenue/total assets=0×

Based on trailing twelve months.

The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 2:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-016982

FAQ

What is Monopar Therapeutics's asset turnover?
Monopar Therapeutics (MNPR) reported asset turnover of 0× in Q1 2026.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.

Ask your AI about Monopar Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude